Episode
Episode 58: CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN) with Dr. Piers Blombery
- Podcast
- Blood Cancer Talks
- Published
- Mar 26, 2025
- Duration seconds
- 3024
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/9da2f779
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-58-car-transgenic-t-cell-lymphoproliferative-neoplasms-cttln-with-dr-piers-blombery/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-58-car-transgenic-t-cell-lymphoproliferative-neoplasms-cttln-with-dr-piers-blombery.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric antigen receptor following cilta-cel treatment for multiple myeloma. As a bonus, we also briefly discussed Dr. Blombery’s paper on menin inhibitors in UBTF tandem duplicated AML. Here are the papers we discussed: 1. CTTLN cases from CARTITUDE-4: https://pubmed.ncbi.nlm.nih.gov/39938094/ 2. CTTLN case from MSKCC with insertional mutagenesis: https://pubmed.ncbi.nlm.nih.gov/39908432/ 3. Other CTTLN cases in myeloma: https://pubmed.ncbi.nlm.nih.gov/38865661/ https://pmc.ncbi.nlm.nih.gov/articles/PMC8417502/ 4. Response and resistance to menin inhibitors in UBTF tandem duplication AML: https://pubmed.ncbi.nlm.nih.gov/38924737/